Login to Your Account



Clinic Roundup


Thursday, April 18, 2013
• Medicago Inc., of Quebec City, and the Infectious Disease Research Institute (IDRI) in Seattle reported interim results from a Phase I trial testing an H5N1 avian influenza virus-like particle vaccine candidate, showing that it was safe and well tolerated and induced a solid immune response exceeding the three Committee for Medicinal Products for Human Use immunogenicity criteria for licensure of influenza vaccines.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription